NEW YORK 1997-03-31 While shares of Columbia/HCA Healthcare Corp took a beating Monday following a federal probe and media reports about its billing practices , industry analysts continued to support the stock .Analysts expect Columbia/HCA's stock to continue to face near-term pressure but said the company will remain a market leader over the long-term .Link: [Comments: s1 explains which stock "the stock" in s2 is.]Columbia/HCA lost 4-3/4 to 33 and was the heavily traded issue on the New York Stock Exchange .The stock will rebound , but I expect continued negative commentary to pressure the stock for the near-term , _" John Hindelong , an analyst with Donaldson , Lufkin & Jenrette .So , the fact that they are only in one location leads one to think that it_ 's not a company-wide issue , _" Joseph Chiarelli , an analyst with J.P. Morgan Securities .The stock has dropped sharply in the past two weeks as news of the federal probe of its El Paso operations surfaced ."_ What would make me uncomfortable is if the government went into other markets and locations at Columbia .Chiarelli said he continues to rate the stock as a buy .Analysts cautioned that the New York Times used its own methodology , which has not been verified by others in the healthcare industry , as the basis of its article .